XML 83 R48.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangible Assets and Goodwill (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Intangible assets          
Total intangible assets, gross $ 7,712.5   $ 7,712.5   $ 7,646.3
Accumulated Amortization (3,842.6)   (3,842.6)   (3,561.2)
Intangible assets, net 3,869.9   3,869.9   4,085.1
Intangible Assets and Goodwill (Textual) [Abstract]          
Amortization of acquired intangible assets 99.7 $ 98.1 281.4 $ 286.0  
Accumulated impairment losses related to goodwill 0.0   0.0    
Expected future amortization expense, 2016 (remaining three months) 92.8   92.8    
Expected future amortization expense, 2017 347.8   347.8    
Expected future amortization expense, 2018 321.4   321.4    
Expected future amortization expense, 2019 301.9   301.9    
Expected future amortization expense, 2020 265.6   265.6    
Expected future amortization expense, 2021 247.7   247.7    
Out-licensed patents          
Intangible assets          
Cost 543.3   543.3   543.3
Accumulated Amortization (519.4)   (519.4)   (506.0)
Net 23.9   $ 23.9   37.3
Out-licensed patents | Minimum          
Intangible assets          
Estimated life, (in years)     13 years    
Out-licensed patents | Maximum          
Intangible assets          
Estimated life, (in years)     23 years    
Developed technology          
Intangible assets          
Cost 3,005.3   $ 3,005.3   3,005.3
Accumulated Amortization (2,619.8)   (2,619.8)   (2,552.9)
Net 385.5   $ 385.5   452.4
Developed technology | Minimum          
Intangible assets          
Estimated life, (in years)     15 years    
Developed technology | Maximum          
Intangible assets          
Estimated life, (in years)     23 years    
Developed technology | AVONEX          
Intangible assets          
Net 377.8   $ 377.8    
Acquired and in-licensed rights and patents          
Intangible assets          
Cost 3,420.2   3,420.2   3,303.2
Accumulated Amortization (703.4)   (703.4)   (502.3)
Net 2,716.8   $ 2,716.8   2,800.9
Acquired and in-licensed rights and patents | Minimum          
Intangible assets          
Estimated life, (in years)     6 years    
Acquired and in-licensed rights and patents | Maximum          
Intangible assets          
Estimated life, (in years)     18 years    
Acquired and in-licensed rights and patents | Biosimilars          
Intangible assets          
Increase in acquired and in-licensed rights and patents 25.0   $ 50.0    
Acquired and in-licensed rights and patents | ZINBRYTA          
Intangible assets          
Increase in acquired and in-licensed rights and patents     32.0    
Acquired and in-licensed rights and patents | ALPROLIX          
Intangible assets          
Increase in acquired and in-licensed rights and patents     26.5    
Contingent payment made during the period     20.0    
Deferred tax liability 6.5   $ 6.5    
In-process research and development          
Intangible assets          
Indefinite lived intangible assets useful life     Indefinite until commercialization    
Cost and Net 679.7   $ 679.7   730.5
Accumulated Amortization 0.0   $ 0.0   0.0
Trademarks and trade names          
Intangible assets          
Indefinite lived intangible assets useful life     Indefinite    
Cost and Net 64.0   $ 64.0   64.0
Accumulated Amortization 0.0   0.0   $ 0.0
TYSABRI product | Acquired and in-licensed rights and patents          
Intangible assets          
Net $ 2,559.9   $ 2,559.9